65 13.4 Appendix D: Modified Choi Criteria .......................................................................... 66 10 Abbreviated Title: Phase I MVA -Brachyury -TRICOM Version Date: September 14, 2016 Confidential 1 INTRODUCTION 1.1 STUDY OBJECTIVES 1.1.1 Primary Objective s 1.1.1.1 To determine the safety and tolerability of escalating doses of MVA-b rachyury -TRICOM vaccine. 1.1.2 Secondary Objectives 1.1.2.1 To evaluate CD8 and CD4 immunologic response as measured by an increase in brachyury -specific T cells.